Table 1. The unknowns on nonalcoholic fatty liver disease (3).

Optimal in vitro and animal models mimicking the disease on which to test response to therapy are missing

Which are its pathogenic drivers?

Knowledge of its natural history is inadequate: why do some individuals progress rapidly?

Methods to identify rapid progressors remain elusive

No agent is approved for its treatment